Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Randomized, controlled, parallel groups, open-label, blinded end-point assessment,
multicenter study, comparing the effects of a low glucose peritoneal dialysis solution,
XyloCore, to glucose solutions (Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova
or Equibalance) only regimen, in patients with End-Stage Renal Disease (ESRD) receiving
Continuous Ambulatory Peritoneal Dialysis (CAPD), over a 6-month study period.